Engflag

Amilip

Quick links to important sections

Amilip

Amilip_IT

Method of action: Antianginal, Antihypertensive, Antispasmodic, Hypotensive, Vasodilator

Treatment option: Hypertension, Angina Pectoris, Prinzmetal Angina

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amilip

What is Amilip? Defining the Drug Entity and Its Form

Property Description
Active ingredient Amlodipine (as besylate)
Form Oral tablet
Pharmacological class Dihydropyridine Calcium Channel Blocker (CCB)
Common use Modulating systemic pressure and supporting blood flow to the heart
Origin Synthetic compound

Amilip is the trade designation for a long-acting, prescription-only medication whose single active component is Amlodipine, typically formulated as the salt Amlodipine besylate. This drug is classified as a synthetic compound and is administered as an oral tablet. Its status as a single-ingredient product designed for long-term daily management is clinically recognized for providing predictable blood level concentrations.

The medication is designed for the foundational management of chronic conditions. It is specifically positioned as a long-acting preparation, distinguishing its dosing frequency from shorter-acting compounds. It is supplied as an oral tablet, which facilitates the steady delivery of the active agent over an extended period.

Amilip's Pharmacological Class: The Calcium Channel Blocker (CCB)

Amilip is categorized as a Dihydropyridine Calcium Channel Blocker (CCB), its established pharmacological class. This classification defines its core action: to regulate the movement of calcium ions into the smooth muscle cells that constitute the walls of the arteries. Amlodipine works by selectively inhibiting calcium influx, leading to the relaxation of arterial smooth muscle.

Within the wider CCB group, the dihydropyridines, such as Amlodipine, are specifically noted for having a greater effect on the vascular system than on the cardiac muscle itself, distinguishing its primary action of promoting widespread peripheral vasodilation.

What is the General Purpose of This Medication?

The general purpose of the medication is to help stabilize and modulate systemic pressure by easing the workload on the cardiovascular system, which supports the long-term maintenance of efficient heart function.

By promoting the widening of blood vessels, the drug effectively reduces the internal resistance to blood flow throughout the circulatory system. This essential function defines the medication as both an Antihypertensive agent, due to its role in modulating high systemic pressure, and an Antianginal agent, which supports improved blood and oxygen supply to the heart muscle. A typical neutral use scenario for this class of drug is the daily management of elevated systemic blood pressure.

Regulatory References

  1. U.S. National Library of Medicine, MedlinePlus
  2. National Institutes of Health

What side effects are possible with Amilip?

Possible Side Effects and Safety Information

The safety profile of Amilip (amlodipine) is defined by officially documented adverse reactions classified by frequency and the physiological systems affected. These classifications are used by regulatory bodies, such as the FDA and EMA, to communicate the risk landscape of the medication.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped based on their observed incidence:

Frequency Tier Examples of Associated Reactions
Common (ge 1/100 to <1/10) Edema (swelling), headache, dizziness, fatigue, nausea, palpitations, and flushing.
Uncommon (ge 1/1,000 to <1/100) Hypotension, arrhythmia, insomnia, and dry mouth.
Very Rare (<1/10,000) Myocardial infarction, hepatitis, jaundice, and severe allergic reactions like angioedema.

Systems and Contextual Safety Patterns

The documented adverse reactions primarily involve the Vascular/Cardiac and Nervous System Disorders. Many common effects, such as headache and somnolence, are more frequently observed at the beginning of treatment.

Label-Documented Safety Considerations

The regulatory safety profile notes specific considerations for certain patient populations. For patients with hepatic impairment, caution is advised due to decreased drug clearance. The label also notes that in studies involving patients with severe heart failure, a higher incidence of pulmonary oedema was reported compared to placebo. Additionally, the possibility of worsening angina or acute myocardial infarction is documented, particularly following the initiation or increase of the dose in individuals with severe coronary artery disease.

Overdose and Emergency Response

The official regulatory profile for an overdose of Amilip focuses on the potential for severe, life-threatening cardiovascular effects. Immediate medical attention is required for any suspected overdose due to the high risk of rapid clinical deterioration.

The primary and most serious documented manifestation of over-ingestion is marked and persistent systemic hypotension, which results from exaggerated peripheral vasodilation. This severe drop in blood pressure can rapidly progress to cardiovascular collapse and shock. Documented clinical presentations may also include dizziness, somnolence (drowsiness), and changes in heart rate, such as reflex tachycardia or, less commonly, bradycardia.

Overdose is classified by regulatory authorities as potentially fatal and necessitates immediate hospitalization for intensive monitoring. Management is defined as symptomatic and supportive. Regulatory documents note that no specific antidote is known, meaning treatment focuses on stabilizing cardiovascular function. Due to the drug’s long elimination half-life, patients may require extended clinical monitoring to address the potential for delayed or persistent hemodynamic instability. Procedures such as gastric lavage or the administration of activated charcoal may be used in a clinical setting to reduce further absorption.

Therapeutic Uses of Amilip

Quick Facts: Amilip (Amlodipine)

  • Main Uses: May be used to manage high blood pressure (hypertension).
  • Support for: Appropriate for the symptomatic care of chronic stable angina (chest pain).
  • Targeted Use: Can be part of a regimen for vasospastic angina (Prinzmetal’s or variant angina).
  • Cardiovascular Support: May reduce the need for hospitalization related to angina and certain coronary procedures in individuals with documented coronary artery disease (CAD).

What Amilip Treats: Main Uses and Benefits

Amilip is a medication that may be used to assist in the long-term management of certain cardiovascular conditions. The primary use of this treatment is for hypertension, or high blood pressure, and it is intended to help lower blood pressure levels. Maintaining blood pressure control is an important element of a comprehensive approach to managing cardiovascular risk factors.

Amilip is also indicated for the care of patients experiencing certain types of chest pain. It provides symptomatic support for chronic stable angina. Additionally, it is an appropriate treatment for vasospastic angina (also referred to as Prinzmetal’s or variant angina), and it may be used alone or in combination with other agents for this purpose.

In individuals with recently documented coronary artery disease (CAD), Amilip may be recommended to reduce the potential for hospitalization related to angina and to reduce the need for certain types of coronary revascularization procedures. These applications define the medication's indications and therapeutic roles in cardiovascular health.

Eligibility and Restrictions for Use

Eligibility for Amilip (Amlodipine) Based on Regulatory Documents

The eligibility for Amilip is strictly defined by regulatory documents based on patient population, age, and existing physiological status. The medicine is contraindicated in patients with a known history of hypersensitivity to Amlodipine or any other dihydropyridine derivatives. Absolute prohibitions also apply to patients experiencing severe hypotension and conditions of circulatory shock, including cardiogenic shock.

Use is generally established for adults for all labeled indications. In pediatric patients, use is restricted to those aged 6 to 17 years solely for hypertension, as safety and efficacy have not been established in children under 6. Older adults and patients with hepatic impairment are eligible but require starting treatment at the lowest end of the dose range due to reduced organ function. Use in patients with renal impairment does not require dose adjustment.

For pregnancy, human safety is not established, and use is only recommended when the benefit outweighs the potential risk. Regulatory labeling advises either discontinuing the drug or discontinuing nursing while breastfeeding, as Amlodipine is excreted into human milk.

These official statements define who can and cannot use the medicine by establishing clear prohibitions based on immune and severe hemodynamic status, conditional use requirements based on organ function, and specific age-related limitations.

What should I know about interactions with other medicines?

Amilip (Amlodipine) is metabolized by the enzyme CYP3A4, which makes it susceptible to interactions with medicines that affect this enzyme system.

Interactions Requiring Close Monitoring or Dose Modification

Interacting Product Category Specific Examples Interaction Result Regulatory Action
Strong/Moderate CYP3A Inhibitors Clarithromycin, Erythromycin, Itraconazole, Ketoconazole, Verapamil, Diltiazem, certain HIV/HCV medications (e.g., Ritonavir) Increased systemic exposure to Amilip, raising the risk of low blood pressure and swelling. Monitoring for symptoms of hypotension and edema; potential Amilip dose reduction.
CYP3A Inducers Rifampicin, St. John's Wort Decreased systemic exposure to Amilip. Close monitoring of blood pressure; potential increase in Amilip dose.
Immunosuppressants Cyclosporine, Tacrolimus Amilip can increase blood levels of these drugs, increasing the risk of toxicity. Frequent monitoring of immunosuppressant trough blood levels and dose adjustment.
Statins Simvastatin Amilip increases Simvastatin exposure, raising the risk of muscle-related side effects. Simvastatin dose must be limited to 20 mg daily.
Antihypertensive Agents Alpha-blockers, ACE inhibitors, Sildenafil Additive blood pressure lowering effect. Close blood pressure monitoring.
Food/Beverage Grapefruit or Grapefruit Juice Potential for increased Amilip bioavailability. Consumption is not recommended.

Mechanism of Action

How Amilip Works

Amilip is a competitive inhibitor of the mevalonate pathway enzyme, Farnesyl Pyrophosphate Synthase (FPPS). This inhibition prevents the prenylation of small G-proteins, including Ras and Rho, within osteoclasts.

Since prenylation is necessary for membrane localization and function, the loss of this modification disrupts the cytoskeletal organization and signaling cascade within the osteoclast cell line. The mechanism ultimately acts by inducing apoptosis in osteoclasts and reducing their maturation and adhesion to the bone matrix surface. This action results in decreased signaling of bone resorption markers. The entire cascade influences the local microenvironment, modulating the paracrine signaling pathways responsible for matrix deposition and subsequent osteoblast differentiation. The molecule exhibits high affinity binding to its target site.

Word Count: 114 words

Dosage and Administration Information

Amilip, which contains the active ingredient amlodipine, is designed for once-daily oral administration. This medication is available in tablet strengths that typically include 2.5 mg, 5 mg, and 10 mg, and it can be taken with or without food. To support long-term, chronic management, the medication should be administered at approximately the same time each day to maintain steady blood concentrations. The tablet should be swallowed whole.

The procedure for establishing the appropriate dose involves a careful, step-wise approach. The typical adult starting dose is 5 mg once daily. Doses are usually maintained within the range of 5 mg to 10 mg, with 10 mg representing the maximum daily dose. Dosage adjustments should not occur frequently; it is typical to wait a minimum of 7 to 14 days between changes to accurately assess the full effect.

Population Group Recommended Initial Dose Maximum Daily Dose
Standard Adult 5 mg 10 mg
Older Adult / Hepatic Impairment 2.5 mg 10 mg
Pediatric (6-17 years) 2.5 mg 5 mg

This 2.5 mg starting dose is also utilized for older adults and individuals with hepatic impairment to account for potential differences in drug processing. If a scheduled dose is missed, it should be taken as soon as it is remembered on that same day; if an entire day has passed, the missed dose should be skipped, and administration should continue with the regular daily dose, without ever taking two doses at once.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Amilip

The research landscape for Amilip (amlodipine) primarily consists of large-scale clinical evaluations, including numerous randomized controlled trials (RCTs) and systematic reviews, as reported by authoritative health bodies. The evidence explores the use of this drug in several long-term cardiovascular conditions. Findings describe group patterns observed in these studies, not personal outcomes or predictions.

Evidence for use in Hypertension (High Blood Pressure)

Amilip was studied for its role in the treatment of high blood pressure through extensive, long-term clinical trials. Research examined changes in both systolic and diastolic blood pressure measurements. The research also explored whether the use of Amilip was associated with differences in the rates of certain major cardiovascular events over time. These studies monitored the incidence of conditions like fatal and nonfatal stroke and myocardial infarction (heart attack).

Evidence for use in Angina (Chest Pain)

Amilip was evaluated in studies examining patient-reported experiences related to chest pain, specifically for treating chronic stable angina and vasospastic angina. Research examined functional outcomes reflecting activity level, such as exercise tolerance time, and patient-reported changes in the frequency of anginal episodes. Research explores short-term symptom changes; however, some long-term research focusing on surrogate measures did not consistently describe changes in the anatomical course of the condition.

Research Gaps and Limitations

Subgroup findings are uncertain or limited for populations that were excluded from the largest trials, such as individuals with severe reductions in heart function. Data for groups such as pregnant women or children are still emerging or remain insufficient, reflecting the regulatory caution typical of evaluating chronic cardiovascular medications in these sensitive populations. Furthermore, comparative evidence is lacking for certain endpoints when Amilip is measured against the newest available drug classes.

Key Studies & References

  1. Amlodipine - StatPearls - NCBI Bookshelf (Review of Indications, including Special Populations)
  2. Amlodipine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Amilip (FAQ)

Q: What should I do if I miss a dose?

A: According to the official product information, specific directions are provided for managing a missed dose of Amilip. These instructions describe the actions to be taken, such as whether a dose can be taken later or if the next scheduled dose should be maintained. This guidance is provided as part of the authorized labeling for safe administration.

Q: Does Amilip interact with grapefruit juice?

A: Official regulatory documents include a dedicated section on food-drug interactions. This information may list substances, such as grapefruit or grapefruit juice, which may carry an official warning against their consumption due to potential interference with how Amilip works.

Q: Can Amilip be crushed or chewed?

A: The approved administration instructions for Amilip specify the correct method for taking the tablet. This information specifies whether the tablet formulation is required to be swallowed whole or if manipulation, such as crushing or dividing, is permitted.

Q: Can I take Amilip with my blood pressure medicine?

A: The official label for Amilip contains a detailed section on known drug-drug interactions. This information details specific drug classes that are known to interact, often recommending caution regarding co-administration.

Q: How long does Amilip take to start working?

A: Studies and official information describe Amilip's pharmacokinetics, which relates to how the body absorbs and processes the medicine. This data helps inform the expected time for the medicine to achieve its maximum concentration in the body.

Q: Will Amilip make me gain weight?

A: The regulatory information includes a comprehensive list of adverse reactions observed during clinical trials. This section notes any documented instances of weight gain or other weight changes that were observed and reported during the drug's clinical studies.

How should Amilip be stored and disposed of?

Storage Requirements

Official regulatory documents stipulate that Amilip (Amlodipine Besylate Tablets) must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and maintained in its tight, light-resistant, original container to preserve stability.

All medication must be stored in a location out of the sight and reach of children.

Disposal Instructions

For disposal of unused or expired Amilip, the FDA recommends utilizing an authorized community drug take-back program. If a take-back option is unavailable, the medicine must be removed from its container, mixed with an undesirable substance, placed in a sealed bag, and then discarded in the household trash. The tablets must not be flushed down the toilet, and all identifying information on the prescription label must be removed prior to container disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPhilippines

Equivalent of Amilip found in:

A-Z Index: